Profile data is unavailable for this security.
About the company
ImmuPharma PLC is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company is focused on developing peptide bio-drugs in specialty therapeutic areas. Its portfolio includes peptide therapeutics for autoimmune diseases and anti-infectives. Its lead program, P140 (Lupuzor), is an autophagy immunomodulator for the treatment of lupus. Its pipeline is focused on two therapeutic areas: autoimmunity/inflammation and anti-infectives. Its pipeline products in autoimmunity and inflammation therapeutic area includes Lupuzor and P140 for CIDP. Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB, a peptide-based drug that offers a potential improvement on the limiting side effects and poor administration regime of Amphotericin-B (AMB) formulations. BioCin, a peptide-based drug based on an existing antibacterial used in high medical need and in many cases as the last line of defense.
- Revenue in GBP (TTM)69.96k
- Net income in GBP-2.99m
- Incorporated2000
- Employees13.00
- LocationImmuPharma PLCOne Bartholomew CloseLONDON EC1A 7BLUnited KingdomGBR
- Phone+44 207 152 4080
- Fax+44 207 152 4001
- Websitehttps://www.immupharma.co.uk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ValiRx Plc | 0.00 | -2.41m | 4.57m | 8.00 | -- | 0.8397 | -- | -- | -0.0256 | -0.0256 | 0.00 | 0.0411 | 0.00 | -- | -- | 0.00 | -69.67 | -58.85 | -69.21 | -68.96 | -- | -- | -- | -- | -- | -575.81 | 0.0072 | -- | -- | -- | -55.87 | -- | -- | -- |
| BSF Enterprise PLC | 12.94k | -1.50m | 5.17m | 4.00 | -- | 1.06 | -- | 399.29 | -0.0159 | -0.0159 | 0.0001 | 0.047 | 0.0028 | 2.11 | 0.0837 | 3,235.00 | -32.30 | -- | -34.46 | -- | -451.16 | -- | -11,600.08 | -- | 8.16 | -154.86 | 0.0313 | -- | -- | -- | -61.40 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.18m | 5.42m | 0.00 | -- | 2.64 | -- | -- | -0.004 | -0.004 | 0.00 | 0.0059 | 0.00 | -- | -- | -- | -48.01 | -- | -51.61 | -- | -- | -- | -- | -- | -- | -6,299.75 | 0.00 | -- | -- | -- | -35.13 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -953.00k | 6.73m | 67.00 | -- | 2.36 | -- | -- | -0.003 | -0.003 | 0.00 | 0.0072 | 0.00 | -- | -- | -- | -35.53 | -134.34 | -37.22 | -227.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 76.74 | -- | -- | -- |
| ImmuPharma PLC | 69.96k | -2.99m | 9.00m | 13.00 | -- | 4.15 | -- | 128.57 | -0.0092 | -0.0092 | 0.0002 | 0.0052 | 0.0227 | -- | 0.1706 | 5,381.54 | -97.05 | -89.69 | -159.35 | -106.57 | -- | -- | -4,275.31 | -7,958.69 | -- | -2.40 | 0.00 | -- | -100.00 | -- | 53.42 | -- | 32.98 | -- |
| Bivictrix Therapeutics PLC | 0.00 | -2.33m | 9.49m | 10.00 | -- | 2.68 | -- | -- | -0.0352 | -0.0352 | 0.00 | 0.0428 | 0.00 | -- | -- | 0.00 | -50.56 | -- | -57.49 | -- | -- | -- | -- | -- | -- | -- | 0.1267 | -- | -- | -- | -6.71 | -- | -- | -- |
| Cambridge Nutritional Sciences PLC | 9.05m | -3.21m | 9.52m | 91.00 | -- | 1.02 | -- | 1.05 | -0.0136 | -0.0105 | 0.0385 | 0.0391 | 0.5857 | 3.97 | 2.05 | 99,406.59 | -20.81 | -10.49 | -23.88 | -11.90 | 52.90 | 59.24 | -35.53 | -27.40 | 4.22 | -128.47 | 0.0225 | -- | -11.63 | -1.96 | -125.12 | -- | -45.83 | -- |
| Proteome Sciences plc | 5.03m | -2.44m | 10.33m | 35.00 | -- | -- | -- | 2.05 | -0.0083 | -0.0083 | 0.017 | -0.0104 | 0.4209 | 3.89 | 3.04 | 143,657.10 | -20.45 | -1.22 | -- | -- | 32.76 | 54.53 | -48.59 | -2.20 | 0.2667 | -2.03 | 1.29 | -- | -35.37 | 10.52 | -284.38 | -- | 126.22 | -- |
| Shield Therapeutics PLC | 7.21m | -46.89m | 10.36m | 28.00 | -- | 0.3486 | -- | 1.44 | -0.1549 | -0.1549 | 0.0151 | 0.038 | 0.1691 | 1.80 | 0.9805 | -- | -109.95 | -42.77 | -129.39 | -48.12 | 44.76 | 79.44 | -650.12 | -274.35 | 2.64 | -124.94 | 0.1756 | -- | 261.55 | 53.86 | -151.04 | -- | -7.68 | -- |
| Kanabo Group PLC | 813.00k | -4.66m | 10.75m | 20.00 | -- | 0.7069 | -- | 13.22 | -0.0108 | -0.0108 | 0.0019 | 0.024 | 0.047 | 8.56 | 27.10 | 40,650.00 | -26.95 | -75.82 | -28.68 | -82.57 | 23.12 | -- | -572.94 | -1,786.10 | 7.96 | -13.03 | 0.041 | -- | 726.03 | -- | -50.96 | -- | -- | -- |
| Chill Brands Group PLC | 146.62k | -3.64m | 11.39m | 2.00 | -- | -- | -- | 77.69 | -0.0142 | -0.0142 | 0.0006 | -0.0024 | 0.0319 | 0.0992 | 0.3639 | 73,310.00 | -79.21 | -72.55 | -141.46 | -105.35 | 53.05 | -- | -2,485.30 | -1,625.46 | 0.6499 | -8.48 | 1.17 | -- | -86.73 | -50.89 | 23.50 | -- | -35.95 | -- |
| Abingdon Health PLC | 5.34m | -2.24m | 12.78m | 82.00 | -- | 7.05 | -- | 2.39 | -0.0184 | -0.0184 | 0.0439 | 0.0149 | 0.8978 | 7.67 | 4.74 | 65,170.73 | -37.55 | -51.31 | -58.04 | -79.85 | 57.35 | 33.16 | -41.82 | -139.64 | 1.59 | -- | 0.3572 | -- | 42.68 | -- | 83.77 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.48m | 12.87m | 8.00 | -- | -- | -- | -- | -0.0192 | -0.0192 | 0.00 | -0.0086 | 0.00 | -- | -- | 0.00 | -373.20 | -101.74 | -- | -132.88 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -36.11 | -- | -- | -- |
| Synairgen plc | 0.00 | -9.99m | 12.89m | 30.00 | -- | 0.8073 | -- | -- | -0.0496 | -0.0496 | 0.00 | 0.0793 | 0.00 | -- | -- | 0.00 | -41.40 | -54.75 | -48.86 | -60.72 | -- | -- | -- | -83,247.62 | -- | -- | 0.00 | -- | -- | -- | 63.74 | -- | 0.00 | -- |
Data as of Apr 25 2024. Currency figures normalised to ImmuPharma PLC's reporting currency: UK Pound GBX
33.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| KW Investment Management Ltd.as of 01 Mar 2024 | 71.29m | 17.12% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 2024 | 20.40m | 4.90% |
| Chelverton Asset Management Ltd.as of 30 Jun 2023 | 15.00m | 3.60% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Mar 2024 | 11.10m | 2.67% |
| IG Markets Ltd.as of 01 Mar 2024 | 10.54m | 2.53% |
| Bank J. Safra Sarasin AG (Investment Management)as of 01 Mar 2024 | 3.26m | 0.78% |
| HSBC Bank Plc (Market-Maker)as of 01 Mar 2024 | 2.56m | 0.62% |
| Jarvis Investment Management Ltd.as of 01 Mar 2024 | 2.44m | 0.59% |
| Close Asset Management Ltd.as of 01 Mar 2024 | 2.24m | 0.54% |
| Aviva Investors Global Services Ltd.as of 20 Apr 2018 | 2.09m | 0.50% |
More ▼
Data from 30 Sep 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
